Start Over

Complement Inhibition in Severe COVID-19 Acute Respiratory Distress Syndrome.

Authors :: Raghunandan S
Josephson CD
Verkerke H
Linam WM
Ingram TC
Zerra PE
Arthur CM
Stowell SR
Briones M
Chonat S
Source :: Frontiers in pediatrics [Front Pediatr] 2020 Dec 29; Vol. 8, pp. 616731. Date of Electronic Publication: 2020 Dec 29 (Print Publication: 2020).
Publication Year :: 2020
Abstract: Most children with COVID-19 have asymptomatic or mild illness. Those who become critically ill suffer from acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI). The rapid deterioration of lung function has been linked to microangiopathic and immune-mediated processes seen in the lungs of adult patients with COVID-19. The role of complement-mediated acute lung injury is supported by animal models of SARS-CoV, evaluation of lung tissue in those who died from COVID-19 and response of COVID-19 ARDS to complement inhibition. We present a summary of a child with COVID-19 disease treated with convalescent plasma and eculizumab and provide a detailed evaluation of the inflammatory pathways.<br />Competing Interests: CJ receives research funds from Terumo BCT, Octapharma and Medtronics. SC is a scientific advisor to Alexion, Novartis and Agios pharmaceuticals. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2020 Raghunandan, Josephson, Verkerke, Linam, Ingram, Zerra, Arthur, Stowell, Briones and Chonat.)